Cartesian Therapeutics said it will focus development of its lead cell therapy candidate on patients with myasthenia gravis and myositis, and will pause work in another immune condition known as systemic lupus erythematosus. That’s despite reporting positive data in a small trial of the lupus patients. The therapy, called Descartes-08, led to remission in two of the three people. Systemic lupus erythematosus, or SLE, affects more than 1.5 million people in the US and can be deadly, inflaming and

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.4 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 (THE “IRISH TAKEOVER RULES”) AND IS NOT AN ANNOUNCEMENT OF A FIRM INT

Applied Therapeutics said its next step will be to request another Type C meeting with the FDA.\n Applied Therapeutics’ lack of progress on govorestat as well as the potential costs to come have led analysts to question whether the biotech will ever be able to get the drug to market.The New York-based company explained yesterday that it had finally received the official minutes from a meeting with the FDA back in September to agree on a path forward for govorestat. The drug is designed to

Isaac Health , a brain health and dementia care platform, has announced a partnership with Oregon-based Atrio Health Plans to increase access to cognitive care for Atrio Medicare Advantage plan members. The partnership will allow Atrio Medicare Advantage plan members with either cognitive issues or who have been diagnosed with dementia to obtain care through Isaac Health's digital platform, which includes specialist diagnosis and treatment services and long-term care management. Additionally, ca

House Rx, a healthcare technology platform that focuses on specialty pharmacy, announced it raised $55 million in Series B equity and debt, bringing the company's total capital to $100 million. The round was led by New Enterprise Associates and Town Hall Ventures . LRVHealth , First Round Capital , Bessemer Venture Partners and Silicon Valley Bank , participated in the round. WHAT IT DOES In contrast to the traditional pharmacy benefit manager-owned business model, House Rx includes a nationwide

Paul Berns was in the middle of a haircut when his phone rang. A month earlier, he had helped steer the biotech he co-founded, Metsera, to a $7.3 billion deal with Pfizer. With the deal signed, Metsera was now focused on integrating with the giant New York drugmaker, and Berns was thinking about what he would do next. But on the other end of the phone was Novo Nordisk CEO Mike Doustdar. It was Saturday, Oct. 25, and a month earlier, Novo had offered as much as $10 billion for Metsera, but lost.

Nove Device creates discreet, everyday-carry kits to hold emergency naloxone nasal sprays, empowering users to respond quickly and without stigma. SAN FRANCISCO, CA, UNITED STATES, November 14, 2025 / EINPresswire.com / -- Nove Device continues to redefine public health preparedness with its innovative single dose nasal spray carry case for life saving medications such as Narcan ® (naloxone HCl), Kloxxado ® (naloxone HCl), Tosymra ® (sumatriptan), Imitrex ® (sumatriptan), Neffy ® (epinephrine na

This kit is designed to educate individuals and communities on recognizing and responding to an overdose effectively. SAN FRANCISCO, CA, UNITED STATES, November 14, 2025 / EINPresswire.com / -- Nove Device has announced the launch of its innovative naloxone nasal spray carry case for emergency use. Committed to improving public safety and accessibility, the company continues to develop smart, reliable solutions designed to make life-saving tools more accessible during critical moments. Design fo

Lundbeck's new drug application (NDA) for Vyepti® (eptinezumab) accepted by Japan's Ministry of Health, Labor and Welfare (MHLW), marking a significant step forward towards expanding access to the novel preventive migraine treatment for patients across Japan Similar marketing authorization applications also accepted in China and South Korea, supported by Phase 3 SUNRISE trial data confirming the preventive efficacy of eptinezumab in Asian patients with migraine The submissions represent a mile

U.K.-based VC Medicxi will channel its new fund toward entrepreneurs creating asset-focused biotechs across all stages of development.\n European life sciences investor Medicxi has raised 500 million euros (about $581.6 million) to go directly toward innovative biotechs.Dubbed Medicxi V, the firm’s sixth fund will support companies “with clear product visions to transform patient care,” according to a Nov. 14 release. The London and Geneva-based VC will channel the money to entrepreneurs